Estrogen Replacement Therapy: Benefits, Risks, and Who Should Consider It

Why Estrogen Matters Beyond Hot Flashes

Estrogen is not merely a reproductive hormone. Estrogen receptors exist in the brain, bone, cardiovascular system, skin, urinary tract, and metabolic tissues. Estrogen's systemic roles include:

• Cardiovascular protection: Estrogen maintains arterial flexibility, improves lipid profiles (raising HDL, lowering LDL), reduces arterial inflammation, and inhibits platelet aggregation
• Bone density maintenance: Estrogen suppresses osteoclast activity; the rapid bone loss in the first 5 years after menopause is driven almost entirely by estrogen withdrawal
• Brain and cognition: Estrogen supports serotonin, dopamine, and acetylcholine systems; estrogen deficiency is associated with mood disorders, brain fog, and increased Alzheimer's risk
• Metabolic function: Estrogen improves insulin sensitivity and helps regulate body fat distribution; loss of estrogen accelerates visceral fat accumulation
• Urogenital health: Estrogen maintains vaginal tissue, lubrication, and urethral integrity; deficiency causes genitourinary syndrome of menopause (GSM)
• Skin and collagen: Estrogen stimulates collagen synthesis; skin loses approximately 30% of its collagen in the first five years after menopause without estrogen support

For more context on how these hormones interact, see our detailed guide on how women's hormones work together.

Rethinking the WHI: What the Data Actually Shows

The Women's Health Initiative (WHI) 2002 study created widespread fear about hormone therapy, but the full picture is nuanced:

• The WHI studied only conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) — a synthetic progestin, not bioidentical progesterone
• The average participant age was 63 — more than a decade past menopause onset, well outside the "timing hypothesis" window for cardiovascular benefit
• Absolute risk increases were small: roughly 8 extra cases of breast cancer per 10,000 women per year in the combination arm — and importantly, women who had hysterectomies and took estrogen alone showed a reduced breast cancer risk
• The estrogen-alone arm of the WHI (women without a uterus) showed no breast cancer increase and showed cardiovascular benefit in women who started within 10 years of menopause

The "timing hypothesis" — now well-established — holds that estrogen therapy started within 10 years of menopause onset (or before age 60) is cardioprotective, while initiation after this window in women with pre-existing atherosclerosis may be neutral or harmful. The Kronos Early Estrogen Prevention Study (KEEPS) and ELITE trial confirmed the cardiovascular benefit of early initiation.

Types of Estrogen Therapy

Routes of Administration

Transdermal estrogen (patches, gels, sprays) bypasses first-pass liver metabolism and is associated with significantly lower risk of blood clots (VTE) and stroke compared to oral estrogen. This is now the preferred route for most women, particularly those with cardiovascular risk factors. A French cohort study of over 80,000 women found no increased VTE risk with transdermal estrogen versus no therapy.

Oral estradiol (not conjugated equine estrogen) is effective and convenient, though it increases clotting factor synthesis due to liver first-pass metabolism. It remains appropriate for many women without VTE risk factors.

Vaginal estrogen (cream, ring, or tablet) delivers estrogen locally with minimal systemic absorption. It effectively treats genitourinary syndrome of menopause (GSM) — vaginal dryness, recurrent UTIs, urinary urgency — and is considered safe even in women with a history of hormone-sensitive breast cancer by most guidelines.

Types of Estrogen

• 17β-estradiol: The dominant pre-menopausal estrogen; bioidentical to what the ovaries produce; available as transdermal patches (Climara, Vivelle-Dot), gels (EstroGel, Divigel), and oral tablets (Estrace)
• Conjugated equine estrogen (CEE/Premarin): Derived from pregnant mare urine; contains a mix of estrogens including some not found in humans; used since the 1940s with extensive safety data but structurally distinct from bioidentical estradiol
• Estriol: A weaker estrogen used primarily in vaginal formulations; not FDA-approved for systemic use but available via compounding

Progesterone Requirement: Who Needs It

Women with an intact uterus must take a progestogen alongside systemic estrogen to protect the uterine lining from endometrial hyperplasia and cancer. Options:

• Micronized progesterone (Prometrium): Bioidentical; the preferred progestogen for most women; associated with better sleep, fewer side effects, and no detectable breast cancer signal in observational data compared to synthetic progestins
• Levonorgestrel IUD: Provides local uterine protection with minimal systemic progestogen exposure — an excellent option for women who tolerate oral progesterone poorly
• Synthetic progestins: Norethindrone, MPA; effective for uterine protection but carry more side effects and a higher breast cancer signal in long-term use

Women who have had a hysterectomy can take estrogen alone — which is associated with better outcomes than combined therapy in WHI analyses.

Benefits Supported by Evidence

Menopause Symptom Relief

Systemic estrogen is the most effective treatment available for vasomotor symptoms (hot flashes, night sweats) — reducing frequency by 75–90% in most women. No non-hormonal therapy approaches this efficacy. Beyond hot flashes, estrogen reliably improves sleep quality, mood, cognitive function, and energy.

Bone Protection

Estrogen therapy is one of the only treatments that both prevents bone loss and reduces fracture risk. WHI participants on hormone therapy had a 24% reduction in hip fracture risk. For women with osteoporosis or significant osteopenia, this benefit is substantial.

Cardiovascular Health in Early Initiators

Women who begin hormone therapy within 10 years of menopause have reduced rates of coronary artery disease, improved lipid profiles, and lower all-cause mortality in multiple observational studies and the ELITE trial. The cardiovascular benefit is one of the most important — and historically underappreciated — reasons to consider early initiation.

Diabetes Prevention

The WHI showed a 21% reduction in new-onset type 2 diabetes with hormone therapy. Estrogen's ability to maintain insulin sensitivity and reduce visceral fat accumulation drives this effect.

Cognitive Protection

Early initiation of estrogen therapy is associated with reduced risk of Alzheimer's disease. The "critical window" concept applies here too — initiating after age 65 appears neutral or potentially harmful for cognition, while early initiation in perimenopause or early post-menopause shows protective effects in observational data.

Risks: A Balanced View

Breast Cancer

The most feared risk. The current evidence suggests: estrogen-alone therapy does not increase breast cancer risk and may reduce it; combined estrogen-progestogen therapy with synthetic progestins carries a modest risk increase with long-term use; combined therapy with bioidentical progesterone appears to carry minimal or no increased risk based on the large EPIC and French Prospective Cohort studies.

Blood Clots

Oral estrogen increases VTE risk by approximately 2-3 fold. Transdermal estrogen does not increase VTE risk significantly. Women with a personal or family history of blood clots should use transdermal estrogen.

Stroke

Oral estrogen modestly increases ischemic stroke risk; transdermal estrogen does not appear to increase stroke risk in low-to-normal doses. Women with significant cardiovascular risk factors should prefer transdermal formulations.

Who Is a Good Candidate?

ERT is most beneficial for women who:

• Are within 10 years of menopause onset or under age 60
• Have moderate-to-severe vasomotor symptoms significantly impacting quality of life
• Have risk factors for osteoporosis or established bone loss
• Experience genitourinary syndrome of menopause
• Have premature ovarian insufficiency (POI) — women under 40 who lose ovarian function should virtually always use HRT until natural menopause age, given the cardiovascular and bone risks of early estrogen deprivation

ERT requires more caution (not necessarily avoidance) in women with active hormone-sensitive breast cancer, untreated endometrial cancer, unexplained vaginal bleeding, active liver disease, or recent cardiovascular events. Each situation requires individualized assessment. To learn more about comprehensive women's hormone health, visit our Learn library or connect with a clinician today.

References

Manson JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. PubMed